The global CAR T-cell therapy market was valued at $1.7 billion in 2022, and is projected to reach $6.1 billion by 2030, growing at a CAGR of 13.5% from 2022 to 2030. The market is being driven by several factors, including the increasing number of clinical trials exploring the use of CAR T-cell therapies, the growing number of cancer patients, and the rising investments in research and development by biotechnology and pharmaceutical companies. 

CAR T-cell therapy is a personalized treatment that is tailored to the individual patient, and this is becoming increasingly important in the field of cancer treatment. Patients are demanding personalized treatments that are more effective and have fewer side effects, and CAR T-cell therapy meets these criteria. Biotechnology and pharmaceutical companies are investing heavily in research and development of CAR T-cell therapies. This is driving the development of new and innovative treatments, and as more therapies become available, the market is expected to grow.

Browse 231 market data Tables and 94 Figures spread through 309 Pages and in-depth TOC on "CAR T-cell Therapy Market Size, Share & Trends Estimation Report By Outlook, By Region, And Segment Forecasts, 2022 - 2030" View detailed Table of Content here-https://www.contrivedatuminsights.com/product-report/car-t-cell-therapy-market-248583/

The limited availability of CAR T-cell therapies is another limiting factor. Currently, only a few centers worldwide are equipped to provide CAR T-cell therapy, which limits the availability of the treatment to patients. Although CAR T-cell therapy has shown great promise in clinical trials, there are still safety concerns associated with the treatment. CAR T-cell therapy can cause serious side effects, including cytokine release syndrome (CRS) and neurotoxicity. These safety concerns could limit the use of CAR T-cell therapy and slow the growth of the market.

Market Dynamics

The global Car T-cell therapy market is segmented into various categories such as indication outlook, end user outlook, drug type outlook, and region. Based on the indication outlook, the global Car T-cell therapy market is segmented into lymphoma, acute lymphocytic leukemia, and others. Based on end users, the global Car T-cell therapy market is segmented into hospitals and cancer treatment centers. Based on drug type outlook, the global Car T-cell therapy market is segmented into Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others. Based on region, the global Car T-cell therapy market is segmented into ??North America, U.S., Canada, Europe, U.K., Germany, France, Italy, Asia Pacific, China, India, Japan, South Korea, Latin America, Brazil, Mexico, and Middle East & Africa.

CAR T-cell therapy has shown promise in the treatment of certain types of cancer, including leukemia and lymphoma. There is potential for the expansion of indications to other types of cancer, which could significantly increase the demand for the treatment. The high cost and complexity of CAR T-cell therapy require significant investment in infrastructure. There is significant potential for the expansion of infrastructure to increase the availability and accessibility of the treatment.

The manufacturing process for CAR T-cell therapy is complex and requires specialized expertise and infrastructure. This can limit the availability of the treatment and make it challenging for healthcare providers to administer. The regulatory approval process for CAR T-cell therapy is complex and time-consuming. This could limit the development and commercialization of new therapies and slow the growth of the market.

DLBCL is the second-largest indication for CAR T-cell therapy, and it is expected to grow significantly in the coming years. The increasing adoption of CAR T-cell therapy as a second-line treatment for DLBCL and the development of new therapies for the disease are the major factors driving the growth of the market.

MCL is another indication for CAR T-cell therapy, and it is expected to grow moderately in the coming years. The limited availability of CAR T-cell therapy for MCL and the development of new therapies for the disease are the major factors driving the growth of the market.

Allogeneic CAR T-cell therapy involves the use of T-cells from a healthy donor that are genetically modified to express a CAR and infused into the patient. This type of CAR T-cell therapy is still in the early stages of development and has the potential to be more cost-effective and accessible than autologous CAR T-cell therapy.

Tandem CAR T-cell therapy involves the use of two CARs on a single T-cell, which allows for the targeting of multiple antigens simultaneously. This type of CAR T-cell therapy is still in the early stages of development and has the potential to be used in a broader range of cancers.

Hospitals are the largest end users of CAR T-cell therapy. This is because hospitals have the necessary infrastructure and expertise to administer CAR T-cell therapy and manage any potential side effects. In addition, hospitals are the primary site for clinical trials that test the safety and efficacy of CAR T-cell therapy. Clinics are also important to end users of CAR T-cell therapy, especially for patients who require ongoing follow-up care and monitoring after receiving the therapy. Clinics may also be used as infusion centers for CAR T-cell therapy.

Regional Analysis

The Asia Pacific region is expected to be the fastest-growing market for CAR T-cell therapy. The increasing prevalence of cancer, improving healthcare infrastructure, and the growing adoption of CAR T-cell therapy are the major factors driving the growth of the market in the region.

The Latin America market for CAR T-cell therapy is expected to grow at a moderate pace. The increasing investment in healthcare infrastructure and the growing adoption of CAR T-cell therapy are the major factors driving the growth of the market in the region.

The Middle East and Africa market for CAR T-cell therapy is expected to grow at a slow pace. The limited availability of CAR T-cell therapy and the high cost of treatment are the major factors limiting the growth of the market in the region. Bristol-Myers Squibb acquired Celgene, which was developing the CAR T-cell therapy Breyanzi, and is now a significant player in the market. Bristol-Myers Squibb is also developing other CAR T-cell therapies for various types of cancer.

Juno Therapeutics, which was acquired by Celgene and is now part of Bristol-Myers Squibb, was a leading developer of CAR T-cell therapies before the acquisition. Juno Therapeutics developed JCAR017, a CAR T-cell therapy for DLBCL, which is now being developed by Bristol-Myers Squibb. Bluebird Bio is developing CAR T-cell therapies for various types of cancer, including multiple myeloma and acute myeloid leukemia. Bluebird Bio is also developing gene therapies for other diseases, such as sickle cell disease and beta-thalassemia.

Segmentation Analysis of The Global CAR T-cell therapy 2012-2030

The report forecasts revenue growth at global, regional, and country matrics and analyzed the latest industry trends in each of the sub-segments ranging from 2016-2030. For this, CDI has segmented the global CAR T-cell therapy market report based on capacity, vehicle, application, and propulsion type along with regional analysis. 

Indication Outlook (Revenue, USD Billion, 2022 - 2030)

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

End User (Revenue, USD Billion, 2022- 2030)

• Hospitals
• Cancer Treatment Centers

Drug Type Outlook (Revenue, USD Billion, 2022 - 2030)

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

Regional Outlook (Revenue, USD Billion, 2022- 2030)

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America